NCOA2 and cancer: As inhibitors of PFKFB3 show recent promise as plausible treatment options for proliferative disorders such as cancer (Wang Y. et al., 2020), targeting PFKFB3 may also be an option to treat endometrial pathologies with an unchecked proliferative phenotype; (3) Does epithelial-derived SRC-2 have a role in endometrial receptivity and decidualization?